A Multi-centre, Randomised, Placebo-controlled, Double-blind, Parallel-group Trial to Evaluate Safety and Efficacy of Spesolimab (BI 655130) in Adult Patients With Ulcerative Pyoderma Gangrenosum (PG) Who Require Systemic Therapy
Latest Information Update: 10 Oct 2024
At a glance
- Drugs Spesolimab (Primary)
- Indications Pyoderma gangrenosum
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 10 Oct 2024 New trial record